(Corrects to compare with first half of 2023 (not year earlier) in paragraph 2, to read 3.3 million euros in paragraph 4)

MADRID, Nov 2 (Reuters) - Grifols shares soared in early trading on Thursday after the Spanish drugmaker upgraded its annual profit outlook following a strong quarter.

Grifols, which posted a third-quarter net profit of 60 million euros ($63.64 million) from a loss in the first half of the year, raised its 2023 guidance for adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) to 1.45 billion euros from range of 1.40-1.45 billion previously.

Its shares were up 9.7% in early trading while the blue-chip IBEX-25 index was up 1.1%.

The company, which uses blood plasma to make medicines, posted a nine-month net profit of 3.3 million euros, while its adjusted EBITDA reached 1.03 billion euros.

Grifols said it managed to cut the cost of collecting plasma by 22% as of September 2023 versus its peak in July 2022.

It said it expects to close the $1.5 billion sale of a stake in Shanghai RAAS in the first half of 2024. The deal was announced in July.

($1 = 0.9435 euros) (Reporting by Marta Serafinko; editing by Inti Landauro and Jason Neely)